Real Patient Results
Weight-management outcomes should be evaluated over time and in the context of the individual treatment plan. This section should feature verified patient progress, when available, with appropriate information about the treatment period and follow-up. Semaglutide is intended to be used with a reduced-calorie diet and increased physical activity for approved weight-management indications. Individual responses vary, and weight reduction is not guaranteed. Your provider can monitor progress using weight and other relevant health measures while considering how well you tolerate treatment.
Why Choose Us?
A prescription weight-management program should account for more than a patient's desired weight. The G Spa's medical approach can help structure treatment around assessment, medication management, and follow-up.
Your provider reviews your health history, medications, weight-management goals, and relevant risk factors before recommending treatment.
Semaglutide dosing is adjusted according to the prescribed product, approved indication, response, and tolerability.
Regular monitoring provides an opportunity to review weight change, side effects, treatment response, and whether the current plan remains appropriate.
Semaglutide is used alongside nutrition and physical activity rather than as a substitute for healthy lifestyle habits.
Your provider can review contraindications, medication interactions, and symptoms that should be reported during treatment.
Benefits
Potential benefits of a medically supervised Semaglutide treatment may include:
Prescription support for long-term weight management in eligible patients
A medication that acts on GLP-1 pathways involved in appetite and food intake
A structured dosing plan that can be adjusted according to tolerability and treatment response
Regular clinical follow-up to assess progress and medication-related concerns
Support for combining medication with reduced-calorie eating patterns and physical activity
A treatment plan that can be reassessed as health status and goals change
Semaglutide may be appropriate for certain adults with obesity or adults who are overweight and have at least one weight-related health condition, depending on the specific FDA-approved indication and clinical assessment. Eligibility is not based on weight alone. A medical consultation is particularly important if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, a history of pancreatitis or gallbladder disease, significant gastrointestinal problems, kidney concerns, diabetes medications, or pregnancy-related considerations. The FDA prescribing information also lists known hypersensitivity to semaglutide or its ingredients as a contraindication.
| Potentially Suitable For | A Consultation Is Important If You Have |
|---|---|
| Adults who meet the eligibility criteria for an FDA-approved semaglutide weight-management indication | A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 |
| Adults with obesity or qualifying overweight and a weight-related condition, depending on the indication | Known hypersensitivity to semaglutide or any ingredient in the prescribed product |
| Patients able to attend follow-up and follow the prescribed dosing schedule | Pregnancy, plans for pregnancy, or breastfeeding considerations requiring medication-specific guidance |
| Patients seeking prescription support alongside nutrition and physical activity | A history of pancreatitis, gallbladder disease, or severe gastrointestinal problems |
| Patients willing to discuss medication response and adverse effects with their provider | Diabetes medications or other medicines that may require closer clinical monitoring |
Treat Yourself To The Glow Up You Deserve at The G Spa.
Save up to $300
$10/Unit for teachers and nurses
1 Treatment - $399
Treatment Journey
Your Semaglutide treatment begins with a medical evaluation and continues with planned follow-up. The exact process depends on the prescribed semaglutide product and your individual health needs.
Your provider reviews your weight history, medical conditions, current medications, allergies, lifestyle factors, and treatment goals. Relevant measurements or laboratory information may be considered when appropriate.
If semaglutide is appropriate, your provider discusses the prescribed product, expected benefits, dosing schedule, potential adverse effects, contraindications, and follow-up plan.
For injectable Wegovy, FDA prescribing information starts treatment at a lower weekly dose followed by gradual escalation. The schedule is designed to improve tolerability. Do not increase, decrease, or change the medication schedule without direction from your prescriber.
Follow-up visits allow the care team to review weight change, appetite, tolerability, relevant health measures, and any symptoms or medication concerns.
Weight management can require continued treatment and lifestyle support. If treatment is stopped, some patients may regain weight. Your clinician can discuss continuation, adjustment, or discontinuation based on your response and health needs.
Google Reviews
Hear directly from patients about their experiences with The G Spa team, treatments, and locations.
Visit Us
Conveniently located in Santa Barbara and Los Olivos, The G Spa offers aesthetic treatments and personalized care at both locations.
Already a G Spa patient? Use our online booking system to schedule your next appointment quickly and conveniently.
Tell us what you are interested in and which location works best for you. A member of our team will follow up with you about your appointment request.
"*" indicates required fields
Blogs
Get helpful information about aesthetic treatments, skin care, injectables, lasers, and other services offered at The G Spa.
FAQ's
Semaglutide is a GLP-1 receptor agonist. FDA-approved Wegovy is used with a reduced-calorie diet and increased physical activity for long-term weight management in certain patients with obesity or overweight with a weight-related condition. The appropriate use depends on the specific product and indication.
Semaglutide activates GLP-1 receptors, pathways involved in appetite and food intake as well as glucose regulation. This can help reduce food intake for some patients. Response varies from person to person.
FDA-approved Wegovy injection is administered subcutaneously once weekly. The prescribing information uses a gradual dose-escalation schedule. Your prescriber will determine the appropriate product and dosing plan for you.
Common adverse reactions reported with Wegovy include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and other gastrointestinal symptoms. Your clinician should review the full safety information and explain symptoms that require prompt medical attention.
Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma, people with Multiple Endocrine Neoplasia syndrome type 2, and people with a known serious hypersensitivity to semaglutide or its ingredients. Pregnancy and other medical conditions require additional clinical assessment.
The response develops over time and varies among patients. Injectable Wegovy is gradually titrated, so the maintenance dose is reached over a period of weeks. Your provider will evaluate your response and tolerability rather than using a single expected timeline.